Intramuscular Neu-Sensamide metoclopramide: Completed Phase I testing in 11 patients, with findings of more than 95 percent bioavailability compared to intraven

OXiGENE Inc. (OXGN), New York Product: Intramuscular Neu-Sensamide metoclopramide Indication: Radiation sensitizer and anti-emetic for cancer therapy Status: Completed Phase I testing in 11 patients, ...